Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) saw a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 23,021 shares, a drop of 51.0% from the June 30th total of 46,964 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 97,056 shares, the days-to-cover ratio is currently 0.2 days.
Straumann Stock Performance
SAUHY stock opened at $11.76 on Tuesday. The company has a 50 day moving average price of $12.28 and a 200 day moving average price of $11.68. Straumann has a fifty-two week low of $9.44 and a fifty-two week high of $13.73.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the stock. Citigroup reaffirmed a “sell” rating on shares of Straumann in a report on Thursday, July 9th. Morgan Stanley reissued an “underweight” rating on shares of Straumann in a report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Straumann in a research report on Tuesday, June 30th. BMO Capital Markets began coverage on Straumann in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Finally, Barclays reaffirmed an “overweight” rating on shares of Straumann in a report on Thursday, June 18th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold”.
Straumann Company Profile
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
See Also
- Five stocks we like better than Straumann
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
